MétaCan
Menu
Back to cohort
Record W4223893598 · doi:10.21203/rs.3.rs-1509838/v1

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review

2022· review· en· W4223893598 on OpenAlexaffabout
Girma Tekle Gebremariam, Atalay Mulu, Kebede Beyene, Beate Sander, Gebremedhin Beedemariam Gebretekle

Bibliographic record

VenueResearch Square · 2022
Typereview
Languageen
FieldMedicine
TopicNeutropenia and Cancer Infections
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsPegfilgrastimMedicineFilgrastimFebrile neutropeniaCost effectivenessChecklistSystematic reviewCochrane LibraryInternal medicineIntensive care medicineOncologyMEDLINENeutropeniaChemotherapyRandomized controlled trial

Abstract

fetched live from OpenAlex

Abstract Background: Febrile neutropenia (FN) is a prevalent and potentially life-threatening complication in patients with lymphoma receiving myelosuppressive chemotherapy. Pegfilgrastim is more effective than filgrastim as prophylaxis for FN. However, its usage has been limited because of its higher cost. Pegfilgrastim's value for money remains unclear.Objective: To systematically review the cost-effectiveness of pegfilgrastim compared to filgrastim for prevention of chemotherapy-induced FN among patients with lymphoma. Methods: A systematic literature search was conducted in PubMed, EMBASE, Cochrane Library databases, and Google Scholar. Only full-economic evaluations were included in the review. Data extraction was guided by the Consolidated Health Economic Evaluation Reporting Standards checklist, and the quality of reviewed articles was assessed using the Joanna Briggs Institute (JBI) checklist. Cost-effectiveness data were rigorously summarized and synthesized narratively. Costs were adjusted to 2020 US$.Results: We identified eight full economic evaluation studies (two cost-utility analyses, three cost-effectiveness analyses, and three studies reporting cost-effectiveness and cost-utility analyses). Half of these studies were from Europe (n=4), the other half were from Iran, USA, Canada and Singapore. Six studies met >80% of the JBI quality assessment criteria. Cost-effectiveness estimates in the majority (n=6) of these studies were for Non-Hodgkin Lymphoma patients receiving myelosuppressive chemotherapy with high-risk of FN (> 20%). The studies considered a wide range of baseline FN risk (17-97.4%) and mortality rates (5.8-8.9%). Reported incremental cost-effectiveness ratios ranged from 2,199US$ to 8,871,600US$ per quality-adjusted life-year (QALY) gained, dominant to 44,358 US$ per FN averted, and 4,261US$-7,251US$ per life-year gained. The most influential parameters were medication and hospitalization costs, relative risk of FN, and assumptions of mortality benefit.Conclusions: Pegfilgrastim appears to be cost-effective primary prophylactic for preventing chemotherapy-induced FN in lymphoma patients. he findings could assist clinicians and healthcare decision-makers to make informed decisions regarding resource allocation for the management of chemotherapy-induced FN in settings similar to those studied.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.008
metaresearch head score (Gemma)0.035
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.012
Threshold uncertainty score0.046

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0080.035
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0120.013
Bibliometrics0.0090.008
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.175
GPT teacher head0.471
Teacher spread0.297 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes2
Has abstractyes

Explore more

Same venueResearch SquareSame topicNeutropenia and Cancer InfectionsFrench-language works237,207